

Stephanie G C Kroeze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3038084/publications.pdf>

Version: 2024-02-01

46
papers

842
citations

471509

17
h-index

477307

29
g-index

50
all docs

50
docs citations

50
times ranked

1671
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. <i>BJU International</i> , 2021, 127, 703-711.	2.5	20
2	Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316.	3.1	34
3	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the "TOAST" database. <i>Radiation Oncology</i> , 2021, 16, 4.	2.7	20
4	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 640467.	2.8	11
5	A Prospective Study on Health-Related Quality of Life and Patient-Reported Outcomes in Adult Brain Tumor Patients Treated with Pencil Beam Scanning Proton Therapy. <i>Cancers</i> , 2021, 13, 4892.	3.7	3
6	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. <i>Cancers</i> , 2021, 13, 4780.	3.7	8
7	True abscopal effect in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 194.	2.7	8
8	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. <i>Melanoma Research</i> , 2020, 30, 552-561.	1.2	5
9	Outcomes of adolescents and young adults treated for brain and skull base tumors with pencil beam scanning proton therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28664.	1.5	8
10	RONC-15. OUTCOMES OF BRAIN AND SKULL-BASE TUMOURS IN ADOLESCENTS AND YOUNG ADULTS TREATED WITH PENCIL BEAM SCANNING PROTON THERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii458-iii458.	1.2	0
11	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 135.	2.7	8
12	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2328-2338.	6.4	13
13	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. <i>BMC Cancer</i> , 2020, 20, 362.	2.6	20
14	PO-1169: Influence of localisation of PSMA-positive oligo-metastases on efficacy of metastasis-directed EBRT. <i>Radiotherapy and Oncology</i> , 2020, 152, S615.	0.6	0
15	OC-0453: Efficacy and safety of stereotactic radiotherapy combined with TKIs for metastatic lesions.. <i>Radiotherapy and Oncology</i> , 2020, 152, S251.	0.6	0
16	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 457-467.	2.2	19
17	OC-0163 Risk classification for PSA relapse after PSMAPET-guided RT for oligorecurrent prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S79-S80.	0.6	0
18	OC-0166 Cumulative metastases volume, not number of brain metastases predicts survival in melanoma patients. <i>Radiotherapy and Oncology</i> , 2019, 133, S81-S82.	0.6	0

#	ARTICLE	IF	CITATIONS
19	EP-1563 PSMA-ligand based radiotherapy for lymph node relapsed prostate cancer after radical prostatectomy. <i>Radiotherapy and Oncology</i> , 2019, 133, S843-S844.	0.6	0
20	OC-0059 Stereotactic radiotherapy for oligoprogressive NSCLC: clinical scenarios affecting survival. <i>Radiotherapy and Oncology</i> , 2019, 133, S23-S24.	0.6	0
21	Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 199-206.	2.0	19
22	Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 889-900.	6.4	44
23	Repeated Courses of Radiosurgery for New Brain Metastases to Defer Whole Brain Radiotherapy: Feasibility and Outcome With Validation of the New Prognostic Metric Brain Metastasis Velocity. <i>Frontiers in Oncology</i> , 2018, 8, 551.	2.8	32
24	EP-1550: Radiotherapy of PSMA-positive oligometastatic recurrent prostate cancer: a single-center experience. <i>Radiotherapy and Oncology</i> , 2018, 127, S836.	0.6	0
25	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. <i>Radiation Oncology</i> , 2018, 13, 90.	2.7	34
26	Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database. <i>Radiation Oncology</i> , 2018, 13, 113.	2.7	6
27	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 53, 25-37.	7.7	169
28	EP-1414: Toxicity of concurrent stereotactic radiotherapy and targeted or immunotherapy: a systematic review. <i>Radiotherapy and Oncology</i> , 2017, 123, S756.	0.6	0
29	The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. <i>World Journal of Urology</i> , 2015, 33, 881-887.	2.2	20
30	1198 CLINICAL EFFICACY OF MULTIPOLAR RADIOFREQUENCY ABLATION OF SMALL RENAL MASSES: A TREAT-AND-RESECT STUDY. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
31	1833 THE BLIND SPOTS IN FOLLOW-UP AFTER NEPHRECTOMY FOR LOCALISED RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
32	Intratumoral Administration of Holmium-166 Acetylacetonate Microspheres: Antitumor Efficacy and Feasibility of Multimodality Imaging in Renal Cancer. <i>PLoS ONE</i> , 2013, 8, e52178.	2.5	29
33	Photodynamic Therapy as Novel Nephron Sparing Treatment Option for Small Renal Masses. <i>Journal of Urology</i> , 2012, 187, 289-295.	0.4	9
34	294 INCOMPLETE THERMAL ABLATION INDUCES INCREASED PROLIFERATION OF RENAL CARCINOMA CELLS IN A MURINE MODEL. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
35	Radio Frequency Ablation Combined with Interleukin-2 Induces an Antitumor Immune Response to Renal Cell Carcinoma in a Murine Model. <i>Journal of Urology</i> , 2012, 188, 607-614.	0.4	9
36	Real-Time 3D Fluoroscopy-Guided Large Core Needle Biopsy of Renal Masses: A Critical Early Evaluation According to the IDEAL Recommendations. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 680-685.	2.0	32

#	ARTICLE	IF	CITATIONS
37	Impact of comorbidity on complications after nephrectomy: use of the Clavien Classification of Surgical Complications. BJU International, 2012, 110, 682-687.	2.5	32
38	Examining the "gold standard"™: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU International, 2012, 110, 1595-1601.	2.5	111
39	Incomplete thermal ablation stimulates proliferation of residual renal carcinoma cells in a translational murine model. BJU International, 2012, 110, E281-6.	2.5	31
40	383 RADIOFREQUENCY ABLATION COMBINED WITH INTERLEUKIN-2 PREVENTS METASTASIS FORMATION IN MOUSE RENAL CELL CARCINOMA. Journal of Urology, 2011, 185, .	0.4	0
41	531 THE IMPACT OF COMORBIDITY ON COMPLICATIONS FOLLOWING NEPHRECTOMY. Journal of Urology, 2011, 185, .	0.4	0
42	2084 HAS MODERN TURP EVOLVED OVER THREE DECADES?: A COMPARATIVE ANALYSIS. Journal of Urology, 2010, 183, .	0.4	0
43	72 INTRATUMORAL ADMINISTRATION OF HOLMIUM LOADED MICROSPHERES AS A NOVEL MINIMALLY INVASIVE THERAPY FOR KIDNEY CANCER; AN ANIMAL STUDY. Journal of Urology, 2010, 183, .	0.4	0
44	86 TOWARDS PHOTODYNAMIC THERAPY AS NOVEL MINIMALLY INVASIVE TREATMENT FOR RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.4	0
45	Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. European Journal of Cancer, 2010, 46, 3375-3382.	2.8	28
46	Assessment of Laparoscopic Suturing Skills of Urology Residents: A Pan-European Study. European Urology, 2009, 56, 865-873.	1.9	56